Kynurenine pathway

Kynurenine pathway dysfunction

Disorders affecting the kynurenine pathway may be primary (of genetic origin) or secondary (due to inflammatory conditions). Peripheral inflammation can lead to a build up of kynurenine in the brain, and this is associated with major depressive disorder, bipolar disorder, and schizophrenia. Dysfunction of the pathway not only causes increase in amounts of metabolites such as quinolinic acid and kynurenic acid but also affects synthesis of serotonin and melatonin. Kynurenine clearance in exercised muscle cells can suppress the build up in the brain.

Hydroxykynureninuria

Also known as kynureninase deficiency, this extremely rare inherited disorder is caused by the defective enzyme kynureninase which leads to a block in the pathway from tryptophan to nicotinic acid mononucleotide (NaMN). As a result, tryptophan is no longer a source of niacin, hence not producing NAD, leading to pellagra (niacin deficiency). Both B6-responsive and B6-unresponsive forms are known. Patients with this disorder excrete excessive amounts of xanthurenic acid, kynurenic acid, 3-hydroxykynurenine, and kynurenine after tryptophan loading and are said to suffer from tachycardia, irregular breathing, arterial hypotension, cerebellar ataxia, developmental retardation, coma, renal tubular dysfunction, renal or metabolic acidosis, and even death. The only biochemical abnormality noted in affected patients was a massive hyperkynureninuria, seen only during periods of coma or after intravenous protein loading. This disturbance was temporarily corrected by large doses of vitamin B6. The activity of kynureninase in the liver was markedly reduced. The activity was appreciably restored by the addition of pyridoxal phosphate.

Acquired and inherited enzyme deficiencies

Downregulation of kynurenine 3-monooxygenase (KMO) can be caused by genetic polymorphisms, cytokines, or both. KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenic acid and anthranilic acid.

Deficiencies of one or more enzymes on the kynurenine pathway leads to an accumulation of intermediate metabolic products which can cause effects depending on their concentration, function and their inter-relation with other metabolic products. For example, kynurenine 3-monooxygenase deficiency is associated with disorders of the brain (such as schizophrenia and tic disorders) and of the liver. The mechanism behind this observation is typically a blockade or bottleneck situation at one or more enzymes on the kynurenine pathway due to the effects of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) and/or due to genetic polymorphisms afflicting the particular genes. Dysfunctional states of distinct steps of the kynurenine pathway (such as kynurenine, kynurenic acid, quinolinic acid, anthranilic acid, 3-hydroxykynurenine) have been described for a number of disorders, for example:

• HIV dementia
• Tourette syndrome
• Tic disorders
• Attention deficit hyperactivity disorder (ADHD)
• Psychiatric disorders (such as schizophrenia, major depressive disorder, bipolar disorder, anxiety disorders)
• Multiple sclerosis
• Huntington's disease
• Encephalopathies
• Lipid metabolism
• Liver fat metabolism
• Systemic lupus erythematosus
• Glutaric aciduria
• Vitamin B6 deficiency
• Eosinophilia-myalgia syndrome
• Long COVID

Research

Research into roles of the kynurenine pathway in human physiology is ongoing.

Neurodegenerative diseases and mental disorders

Scientists are investigating the role of dysregulation of this pathway in aging, neurodegenerative diseases, mental disorders, somatic symptom disorders, and chronic fatigue syndrome (CFS).

Kynurenine/tryptophan ratio

Changes in the ratio of kynurenine versus tryptophan are reported for many diseases like arthritis, HIV/AIDS, neuropsychiatric disorders, cancer and inflammations. The kynurenin/tryptophan is also an indicator for the activity of indoleamine 2,3-dioxygenase (IDO).

Methods

Kynurenine metabolites can be quantified using liquid chromatography coupled to mass spectrometry.

Related substrates

In some species, the kynurenine pathway also processes 6-bromotryptophan, leading to the analogous series of brominated metabolites. These and subsequent derivatives are believed to be responsible for the biofluorescence observed in the skin of the swell shark and the chain catshark.

References

References

1. (11 November 2022). "The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview.". European Psychiatry.
2. (July 2021). "The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites.". Molecular Psychiatry.
3. (25 January 2020). "The kynurenine pathway: a finger in every pie.". Molecular Psychiatry.
4. (2019-01-01). "Tumor Immunology and Immunotherapy – Molecular Methods". Academic Press.
5. (August 2021). "The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies". Molecular Psychiatry.
6. (17 May 2021). "The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites.". Schizophrenia Research.
7. (September 2020). "Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis". Schizophrenia Research.
8. (September 2018). "Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies". Neuroscience and Biobehavioral Reviews.
9. (2015). "What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?". Expert Review of Neurotherapeutics.
10. (July 2014). "Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females". In Vivo (Athens, Greece).
11. (July 2019). "Physical activity and muscle-brain crosstalk.". Nature Reviews. Endocrinology.
12. (28 July 2017). "Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health.". Science.
13. (1996). "Congenital non-progressive encephalopathy and deafness with intermittent episodes of coma and hyperkynureninuria". Journal of Inherited Metabolic Disease.
14. (January 1967). "Hydroxykynureninuria". American Journal of Diseases of Children.
15. (November 1985). "Lethal familial pellagra-like skin lesion associated with neurologic and developmental impairment and the development of cataracts". Pediatrics.
16. (October 1967). "Vitamin B₆ dependent xanthurenic aciduria". The Tohoku Journal of Experimental Medicine.
17. "Neurobiochemie und Psychopharmakologie". Klinikums der Universität München.
18. (February 2011). "Inflammatory biomarkers and depression". Neurotoxicity Research.
19. (July 2011). "Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes". Archives of General Psychiatry.
20. (January 2012). "Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls". Journal of Psychiatry & Neuroscience.
21. (2014). "Kynurenines in CNS disease: regulation by inflammatory cytokines". Frontiers in Neuroscience.
22. (June 2007). "Plasma kynurenine and related measures in tic disorder patients". European Child & Adolescent Psychiatry.
23. (2014). "Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity". PLOS ONE.
24. (October 1967). "Fatty liver induced by injection of L-tryptophan". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism.
25. (September 2002). "Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation". Life Sciences.
26. (June 2001). "Kynurenines in the CNS: from endogenous obscurity to therapeutic importance". Progress in Neurobiology.
27. (January 2024). "The Kynurenine Pathway in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Blood Concentrations of Tryptophan and Its Catabolites". Journal of Clinical Medicine.
28. Lucette, A. Cysiq. (2022). "Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study".
29. (2023). "Long COVID: major findings, mechanisms and recommendations". [[Nature Reviews Microbiology]].
30. Dogrul, Bekir Nihat. (2022-03-01). "Indolamine 2,3-dioxygenase (IDO) inhibitors as a potential treatment for somatic symptoms". Medical Hypotheses.
31. Blankfield, Adele. (2013-07-21). "Article Commentary: Kynurenine Pathway Pathologies: Do Nicotinamide and Other Pathway Co-Factors have a Therapeutic Role in Reduction of Symptom Severity, Including Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM)". International Journal of Tryptophan Research.
32. (June 2013). "Tryptophan metabolism: entering the field of aging and age-related pathologies". Trends in Molecular Medicine.
33. (July 2012). "Kynurenines in the mammalian brain: when physiology meets pathology". Nature Reviews. Neuroscience.
34. (April 1998). "Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients". Clinical Chemistry.
35. (September 2003). "Increased degradation of tryptophan in blood of patients with rheumatoid arthritis". The Journal of Rheumatology.
36. (March 2010). "Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer". Lung Cancer (Amsterdam, Netherlands).
37. (2021-07-17). "Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial". Journal of Neuroinflammation.
38. (December 1997). "Simultaneous measurement of serum tryptophan and kynurenine by HPLC". Clinical Chemistry.
39. (1990). "Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms". Journal of Acquired Immune Deficiency Syndromes.
40. (2009). "Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry". Rapid Communications in Mass Spectrometry.
41. (2019). "Bright Green Biofluorescence in Sharks Derives from Bromo-Kynurenine Metabolism". iScience.